- Home
- VERO vs ZVSA Comparison
VERO vs ZVSA Comparison
Compare VERO & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- ZVSA
- Stock Information
- Founded
- VERO N/A
- ZVSA 2014
- Country
- VERO Canada
- ZVSA United States
- Employees
- VERO N/A
- ZVSA N/A
- Industry
- VERO Medical/Dental Instruments
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- ZVSA Health Care
- Exchange
- VERO Nasdaq
- ZVSA Nasdaq
- Market Cap
- VERO 2.2M
- ZVSA 2.5M
- IPO Year
- VERO N/A
- ZVSA N/A
- Fundamental
- Price
- VERO $3.18
- ZVSA $0.65
- Analyst Decision
- VERO
- ZVSA
- Analyst Count
- VERO 0
- ZVSA 0
- Target Price
- VERO N/A
- ZVSA N/A
- AVG Volume (30 Days)
- VERO 3.1M
- ZVSA 968.0K
- Earning Date
- VERO 05-15-2025
- ZVSA 06-17-2025
- Dividend Yield
- VERO N/A
- ZVSA N/A
- EPS Growth
- VERO N/A
- ZVSA N/A
- EPS
- VERO N/A
- ZVSA N/A
- Revenue
- VERO $60,997,000.00
- ZVSA N/A
- Revenue This Year
- VERO N/A
- ZVSA N/A
- Revenue Next Year
- VERO $7.47
- ZVSA N/A
- P/E Ratio
- VERO N/A
- ZVSA N/A
- Revenue Growth
- VERO N/A
- ZVSA N/A
- 52 Week Low
- VERO $2.10
- ZVSA $0.47
- 52 Week High
- VERO $17.49
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- VERO 65.91
- ZVSA 54.57
- Support Level
- VERO $2.31
- ZVSA $0.60
- Resistance Level
- VERO $2.49
- ZVSA $0.73
- Average True Range (ATR)
- VERO 0.24
- ZVSA 0.07
- MACD
- VERO 0.09
- ZVSA 0.02
- Stochastic Oscillator
- VERO 50.00
- ZVSA 64.83
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.